The Patent Finder
HI

Huyabio International, LLC

First filing 2012
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Previously recorded as Huya Bioscience International, LLC (to 2021)

17 patents currently held

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Nov 2030. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
6
Ending by 2030
Nov 2030
Next term end
9
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents fee due within 90 days all others Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Combination Therapies of Hdac Inhibitors and PD-1 Inhibitors US 10,385,130
The most cited patent in this portfolio, cited by 45 later US patents, top 5% of utility patents granted in 2019 in our data. Protection runs to 2037. A terminal disclaimer caps this term to an earlier patent's.
Ends May 2037 · High confidence
Also notable
Sulcardine Salts US 11,426,382
Cited by 5 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2040. A terminal disclaimer caps this term to an earlier patent's.
Ends Jan 2040 · High confidence
Also notable
Sulcardine Administration for Treatment of Acute Atrial Fibrillation US 11,364,223
Granted 2022. Computed term ends 2030. A terminal disclaimer caps this term to an earlier patent's.
Ends Nov 2030 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Feb 20, 2027
  • 1 fee due May 14, 2027
    The maintenance fee for Sulcardine Administration for Treatment of Acute Atrial Fibrillation (US 11,813,245) comes due May 14, 2027. Unpaid by Nov 15, 2027, it lapses early.
  • 1 fee due Jul 30, 2027
    The maintenance fee for Sulcardine Administration for Treatment of Acute Atrial Fibrillation (US 11,883,380) comes due Jul 30, 2027. Unpaid by Jan 31, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

The largest of its 9 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 8,541,464Treatment of Atrial Fibrillation
In force
 · High confidence
In forceHigh confidence
US 11,364,223Sulcardine Administration for Treatment of Acute Atrial Fibrillation
In force
 · High confidence
In forceHigh confidence
US 11,813,245Sulcardine Administration for Treatment of Acute Atrial Fibrillation
In force
 · High confidence
In forceHigh confidence
US 11,883,380Sulcardine Administration for Treatment of Acute Atrial Fibrillation
In force
 · High confidence
In forceHigh confidence
US 12,357,611Sulcardine Administration for Treatment of Acute Atrial Fibrillation
In force
 · High confidence
In forceHigh confidence
US 12,465,587Sulcardine Administration for Treatment of Acute Atrial Fibrillation
In force
 · High confidence
In forceHigh confidence
US 8,637,566Slow Infusion of Sulcardine and Its Salts
In force
 · High confidence
In forceHigh confidence
US 10,287,353Combination Therapies of Hdac Inhibitors and PD-1 Inhibitors
In force
 · High confidence
In forceHigh confidence
US 10,385,130Combination Therapies of Hdac Inhibitors and PD-1 Inhibitors
In force
 · High confidence
In forceHigh confidence
US 10,385,131Combination Therapies of Hdac Inhibitors and PD-L1 Inhibitors
In force
 · High confidence
In forceHigh confidence
10 of 17 patents shown.
Pro members see all 17.
Pro members: see all 17 patents
Also on record, not counted in the 17: 16 applications pending · 2 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited